Review Article
A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases
Table 1
Summary of results for liver-directed therapy of neuroendocrine tumour liver metastases.
| Modality author [Ref] | Intervention | Number of patients | Overall survival (5 years) | Median survivals (months) | Progression/disease-free survival | Clinical response | Biochemical response | Radiological response |
| Liver surgery | | | | | | | | |
| Sarmiento et al. [3] | Resection | 170 | 61% | | | | | | Touzios et al. [4] |
Resection ± ablation | 18 | 72% | >96 | | | | | Grazi et al. [5] | Resection | 19 | 92% (4 yrs) | | | | | | Kianmanesh et al. [6] | Resection | 23 | 94% | | 50% (5 yrs) | | | | Gomez et al. [7] | Resection | 18 | 86% | | 66% (5 yrs) | | | | Scigliano et al. [8] | Resection | 41 | 79% | | 3% (5 yrs) | | | | Osborne et al. [9] | Cytoreduction | 61 | | Curative-50 (mean) | | | | | | | | | Palliative-32 (mean) | | | | | Musunuru et al. [10] |
Resection ± ablation | 13 | 83% (3 yrs) | | | | | | Mayo et al. [11] |
Resection ± ablation | 339 | 74% | 125 | | | | |
| Liver transplantation | | | | | | | | |
| Lehnert [12] | | 103 | 47% | | | | | | Olausson et al. [13] | | 15 | 90% | | 20% (5 years) | | | | Le Treut et al. [14] | | 85 | 47% | | | | | |
| Embolisation | | | | | | | | |
| Ho et al. [15] | TAE or TACE | 46 | | 42 | 18 months | | | | Ruutiainen et al. [16] | TACE | 57 | 50% | | 35% (3 yrs) | | | | Strosberg et al. [17] | TAE | 84 | | 36 | | | | | Dong and Carr [18] | TACE | 123 | 36% | 39 (mean) | | | | | Ruszniewski et al. [19] | TACE | 24 | | | | 73% | 57% | 33% | Gupta et al. [20] | TAE or TACE | 69 (Carcinoid) | | | 22 months | | | 67% | | | 54 (Pancreatic) | | | 16 months | | | 35% |
| RFA | | | | | | | | |
| Mazzaglia et al. [21] | | 63 | | 46 (after RFA) | | 70% | | |
| SIRT | | | | | | | | |
| King et al. [22] | | 37 | | 29 (mean) | | 55% | 43% | 50% | Kennedy et al. [23] | | 148 | | 70 | | | | 63% | Cao et al. [24] | | 58 | 47% (3 yrs) | 36 | | | | 34% | Saxena et al. [25] | | 48 | | 35 | | | | 55% |
|
|